Funding supports late-stage clinical development, including pivotal Phase 3 clinical trial to support licensure OWS award funds large-scale manufacturing of NVX-CoV2373, including production of 100 million doses starting in late 2020 GAITHERSBURG, Md....More>>

Frank Czworka appointed SVP, Global Sales Brian Webb promoted to SVP, Manufacturing GAITHERSBURG, Md. , July 02, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the...More>>

GAITHERSBURG, Md. , June 29, 2020 (GLOBE NEWSWIRE) -- Novavax , Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Ben Machielse as Executive Vice President, CMC, with responsibility for...More>>

GAITHERSBURG, Md. , June 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino , Senior Vice President, Chief Business Officer and Chief Financial...More>>

Dr. Filip Dubovsky appointed SVP, Chief Medical Officer Silvia Taylor appointed SVP, Investor Relations and Corporate Affairs GAITHERSBURG, Md. , June 17, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious...More>>

GAITHERSBURG, Md. , June 16, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has appointed David Mott as an independent director to its Board of Directors. Mr....More>>

GAITHERSBURG, Md. , June 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has entered into an agreement to sell Series A Convertible preferred stock, convertible...More>>

GAITHERSBURG, Md. , June 08, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn , M.D., President of Research and Development, will join other vaccine...More>>

$60 million funding for manufacturing of NVX-CoV2373 10 million doses to be delivered to DoD in 2020 GAITHERSBURG, Md. , June 04, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...More>>

Novavax acquires Praha Vaccines in Czech Republic Annual operating capacity of over 1 billion doses of COVID-19 vaccine antigen GAITHERSBURG, Md. , May 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious...More>>

First participants enrolled in Phase 1 portion of clinical trial of NVX‑CoV2373 Preliminary immunogenicity and safety results expected in July 2020 Phase 2 portion to begin promptly following successful Phase 1 results GAITHERSBURG, Md. , May 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

CEPI increases investment up to $388 million for NVX‑CoV2373 vaccine development & manufacturing NVX ‑ CoV2373 Phase I trial initiating in May with preliminary results in July NanoFlu recently achieved all primary endpoints in pivotal Phase 3 clinical trial Company to host conference call today at...More>>

Funds clinical development of NVX-CoV2373 through Phase 2 Supports rapid scale-up of vaccine manufacturing Allows for increased production of Matrix-M adjuvant Reserves global large-scale manufacturing capacity GAITHERSBURG, Md. , May 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , May 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory Glenn , M.D., President of Research and Development, will present progress of...More>>

GAITHERSBURG, Md. , May 06, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its first quarter 2020 financial and operating results following the close of...More>>

NVX-CoV2373 identified as SARS-CoV-2 candidate for Phase 1 clinical trial In preclinical studies, NVX-CoV2373 demonstrated high immunogenicity and stimulated high levels of neutralizing antibodies First-in-human Phase 1 clinical trial accelerated to mid-May with preliminary results in July GMP...More>>

Trial also achieves statistical significance in key secondary endpoints Novavax to submit a U.S. BLA under FDA’s accelerated approval pathway Company to host investor conference call today at 8:30 a.m. EDT GAITHERSBURG, Md. , March 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

NanoFlu top-line data from Phase 3 clinical trial expected by the end of this month Novavax awarded CEPI funding to support COVID-19 vaccine program COVID-19 Phase 1 clinical trial expected to initiate in late spring of 2020 Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md....More>>

Novavax’ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University Phase 2b clinical efficacy study of experimental malaria vaccine with Matrix‑M nearing completion in Burkina Faso GAITHERSBURG, Md....More>>

CEPI to provide an initial $4 million to accelerate vaccine development to prepare for Phase 1 Multiple vaccine candidates being tested in preclinical studies prior to advancing to human trials Phase 1 clinical trial expected to initiate in late spring of 2020 GAITHERSBURG, Md....More>>

GAITHERSBURG, Md. , March 05, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its fourth quarter 2019 financial and operating results following the close of...More>>

Vaccine candidate derived from coronavirus spike (S) protein Matrix-M™ adjuvant expected to boost immune responses Phase 1 clinical trial planned for late spring GAITHERSBURG, Md. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing...More>>

GAITHERSBURG, Md. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a publication in Vaccines describing the immunogenic potential of NanoFlu™, Novavax’...More>>

GAITHERSBURG, Md. , Jan. 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation for...More>>

GAITHERSBURG, Md. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference ....More>>

NanoFlu pivotal Phase 3 clinical trial initiated October 2019 with top-line data expected in the first quarter of 2020 Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company...More>>

GAITHERSBURG, Md. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2019 financial and operating results following the close of...More>>

First participants enrolled in pivotal Phase 3 clinical trial of NanoFlu   Top-line clinical data expected in the first quarter of 2020   Phase 3 results expected to support a future BLA and licensure of NanoFlu using the FDA’s accelerated approval pathway GAITHERSBURG, Md. , Oct....More>>

GAITHERSBURG, Md. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck , President and Chief Executive Officer, will present at the Ladenburg...More>>

GAITHERSBURG, Md. , Sept. 06, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck , President and Chief Executive Officer, will present at the H. C....More>>

Data demonstrate significant vaccine efficacy against infant pneumonia through the first year of life GAITHERSBURG, Md., August 12, 2019 – Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the...More>>

GAITHERSBURG, Md. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Louis F. Fries III , M.D., Senior Vice President, Chief Medical Officer, will participate...More>>

Agreement with the FDA on Phase 3 non-inferiority immunogenicity study design for NanoFlu™ NanoFlu pivotal Phase 3 clinical trial expected to initiate in the third quarter of 2019 with top-line data in the first quarter of 2020 Strategic partnership completed with Catalent ; raised $18 million...More>>

Clinical trial expected to initiate in the fall of 2019 GAITHERSBURG, Md. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it received input from the U.S....More>>

Gaithersburg, Md. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2019 financial and operating results following the close of...More>>

GAITHERSBURG, Md., July 31, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Catalent Biologics’ Paragon Gene Therapy unit, the leading viral vector development and manufacturing...More>>

Pivotal Phase 3 clinical trial expected to initiate in the fall of 2019 Top-line clinical data expected in the first quarter of 2020 GAITHERSBURG, Md. , June 27, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious...More>>

Manufacturing equipment and related assets to be sold to Catalent’s Paragon Gene Therapy for $18 million in cash Over 100 manufacturing and quality employees to join Catalent Paragon Gene Therapy to take over two clinical development and manufacturing sites in Gaithersburg, MD Long-term agreement...More>>

GAITHERSBURG, Md. , June 10, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced updates on the pursuit of global licensure for ResVax™ following the Prepare™ Phase 3 clinical...More>>

GAITHERSBURG, Md. , June 04, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced that John J. Trizzino , Senior Vice President, Chief Business Officer and Chief Financial Officer, will join other vaccine industry leaders for a panel discussion at the 2019 BIO International...More>>

GAITHERSBURG, Md. , May 10, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes due 2023 (Notes), pursuant to that certain Indenture between Novavax and The Bank of New York Mellon Trust...More>>

GAITHERSBURG, Md. , May 08, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will effect a one-for-twenty reverse stock split of its issued and outstanding common stock. Stockholders of Novavax approved an amendment to Novavax’ Second Amended and Restated Certificate of...More>>

             Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md. , May 02, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2019 ....More>>

GAITHERSBURG, Md. , May 01, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Flor M. Muñoz, M.D., M.Sc., Associate Professor of Pediatrics Molecular Virology and Microbiology at Baylor College of Medicine and Medical Director, Transplant Infectious Diseases, Texas...More>>

GAITHERSBURG, Md. , April 25, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2019 financial and operating results following the close of U.S. financial markets on Thursday, May 2, 2019 . Conference call details are as follows:       Date:  ...More>>

GAITHERSBURG, Md. , April 09, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Gregory M. Glenn , M.D., President of Research and Development, will share data from its global Phase 3 clinical trial of ResVax™, the respiratory syncytial virus (RSV) fusion (F) protein...More>>

Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md. , March 18, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018 ....More>>

GAITHERSBURG, Md. , March 11, 2019 (GLOBE NEWSWIRE) --Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and year-end 2018 financial and operating results following the close of U.S. financial markets on Monday, March 18, 2019....More>>

Trial did not meet primary objective of prevention of medically significant RSV LRTI Trial did show efficacy against secondary objective (RSV LRTI hospitalization); first RSV vaccine to show Phase 3 efficacy Other pre-specified exploratory endpoints and post-hoc analyses highlight potential to...More>>

Sets the Stage for Phase 3 Clinical Trial in 2019 Phase 2 clinical trial confirmed Phase 1/2 results, again demonstrating improved immune responses over Fluzone ® High-Dose End-of-Phase 2 meeting with the FDA expected in the first half of 2019 Pivotal Phase 3 clinical trial expected to initiate in...More>>

GAITHERSBURG, Md. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference . Presentation details are as follows: Date and time: Wednesday, January 9 , 3:00 p.m. – 3:25 p.m. P.T....More>>

GAITHERSBURG, Md. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced the promotion of Jill Hoyt to Senior Vice President of Human Resources and Biegie Lee to Vice President of Information Technology. “I am thrilled to announce these two important management promotions;...More>>

GAITHERSBURG, Md. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced several management promotions. “We are pleased to announce several key management promotions to further support the advancement of our company and its lead clinical programs into commercial stage,"...More>>

Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter and nine months ended September 30, 2018 ....More>>

GAITHERSBURG, Md. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, November 7, 2018 . Conference call details are as follows: Date: ...More>>

GAITHERSBURG, Md. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq: NVAX) today announced the appointment of Rachel King , Co-Founder and Chief Executive Officer of GlycoMimetics, Inc. , to its Board of Directors. In addition to extensive experience as an executive in the biotechnology...More>>

GAITHERSBURG, Md. , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that its representatives will share data from its RSV F vaccine program via oral and poster presentations at IDWeek 2018 in San Francisco, California , taking place October 3-7 and at the 11th...More>>

GAITHERSBURG, Md. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that it will present at the Ladenburg Thalmann 2018 Healthcare Conference and the Cantor Global Healthcare Conference 2018, both in the first week of October....More>>

First participants enrolled in Phase 2 clinical trial of quadrivalent NanoFlu formulations Top-line immunogenicity and safety data expected in the first quarter of 2019 Phase 2 results will support meeting with the U.S. Food and Drug Administration ( FDA ) and Phase 3 clinical trial design...More>>

GAITHERSBURG, Md. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Novavax will participate in the B. Riley FBR Annual Healthcare Conference and the Citi 13 th Annual Biotech Conference in September. Conference details are as follows: B....More>>

Novavax Delivers on Key Milestones Supporting its 2018 Objectives Company to Host Conference Call Today at 4:30 pm ET GAITHERSBURG, Md. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter and six ...More>>

GAITHERSBURG, Md. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its second quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, August 8, 2018 . Conference call details are as follows: Date: August...More>>

NanoFlu TM Phase 1/2 trial data published in a peer-reviewed letter to the editor in The New England Journal of Medicine NanoFlu demonstrates significantly improved immune responses against a panel of homologous and drifted A(H3N2) influenza viruses compared to leading licensed egg-based, high-dose ...More>>

Title: “The Global Vaccine Business: A View from the Top” Date and Time: Tuesday, June 5, 12:15 p.m. Moderator: Jacqueline Keith, MA, PhD, President, J Keith Consulting Group   Panelists: Stanley Erck, President and Chief Executive Officer, Novavax David Loew, Head, Global Commercial Operations,...More>>

GAITHERSBURG, Md. , May 09, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced its financial results for the first quarter ended March 31, 2018 . First Quarter and Subsequent Achievements: RSV F Vaccine In May 2018 , Novavax reached enrollment of approximately 4,600 pregnant ...More>>

Prepare trial is assessing the efficacy of Novavax’ RSV F Vaccine for infants via maternal immunization Enrollment of ~4,600 participants enables initiation of interim efficacy analysis Topline efficacy data from analysis expected in the first quarter of 2019 GAITHERSBURG, Md. ...More>>

GAITHERSBURG, Md. , May 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, May 9, 2018 . Conference call details are as follows: Date:   May 9, ...More>>

GAITHERSBURG, Md. , April 16, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced the closing of the underwritten public offering priced on Wednesday, April 11, 2018 . ...More>>

GAITHERSBURG, Md. , April 11, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced that it has priced an underwritten public offering of 30,303,050 shares of common stock ...More>>

GAITHERSBURG, Md. , April 11, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced that it intends to offer to sell, subject to market and other conditions, shares of its ...More>>

Update on RSV F Vaccine Phase 3 Prepare ™ trial for infants via maternal immunization Results from Phase 1/2 trial of NanoFlu vaccine demonstrating improved immune responses compared to egg-based, high-dose flu vaccine GAITHERSBURG, Md. , April 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. ...More>>

RSV Phase 3 Prepare™ Trial Outcome De-risked by Successful Informational Analysis NanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine John J. Trizzino Appointed Chief Business Officer and Chief Financial Officer (as Announced in Separate Press...More>>

Gaithersburg, MD, March 14, 2018 – Novavax, Inc., (Nasdaq: NVAX) today announced the promotion of John J. Trizzino to Senior Vice President, Chief Business Officer (CBO) and Chief Financial Officer (CFO). Mr. Trizzino has been serving as Senior Vice President, Commercial Operations, since 2014....More>>

...More>>

RSV F Vaccine informational analysis completed in fourth quarter of 2017 RSV F Vaccine interim analysis expected mid-2018 with approximately 4,600 enrollees Filing of RSV F Vaccine BLA anticipated by late 2019 NanoFlu Vaccine data package to be completed and released in February 2018 GAITHERSBURG,...More>>

GAITHERSBURG, Md. , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced the Company will present at the Stifel 2017 Healthcare Conference. Presentation details are as follows: Date: Wednesday, November 15, 2017 Time: 1:15 p.m. – 1:55 p.m....More>>

GAITHERSBURG, Md. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced its financial results for the third quarter and nine months ended September 30, 2017 . Third Quarter Achievements: Novavax initiated a Phase 1/2 clinical trial of its nanoparticle influenza vaccine...More>>

GAITHERSBURG, Md. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter financial and operating results following the close of U.S. financial markets on Tuesday, November 7, 2017 . Conference call details are as follows: Date: Tuesday,...More>>

GAITHERSBURG, Md. , Oct. 13, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) announced today that Barclay A. “Buck” Phillips has submitted his resignation as Senior Vice President, Chief Financial Officer (CFO) and Treasurer, to pursue an expanded opportunity in the industry. Mr....More>>

GAITHERSBURG, Md. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced the Company will present at the Ladenburg Thalmann 2017 Healthcare Conference. Presentation details are as follows: Date: Tuesday, September 26, 2017 Time: 11:00 – 11:25 am ET Location: Track 5,...More>>

Recently published NanoFlu™ preclinical data provide strong rationale for Phase 1/2 clinical trial based on robust antibody titers and improved protective responses against both current and drifted strains Data from trial expected by the end of 2017 GAITHERSBURG, Md. , Sept....More>>

GAITHERSBURG, Md. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced the Company will participate in Citi’s 12 th Annual Biotech Conference . Conference details are as follows: Date: Thursday, September 7, 2017 Location: Mandarin Oriental hotel, Boston, MA About...More>>

Novel vaccine candidate, NanoFlu™, outperforms market-leading Fluzone® High Dose based on antibody titers and neutralization of recent and historic influenza viruses in a preclinical study GAITHERSBURG, Md. , Aug. 23, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced its financial results for the second quarter and six months ended June 30, 2017 . Second Quarter and Subsequent Achievements: Novavax’ nanoparticle flu vaccine demonstrates superior immunogenicity and...More>>

Novavax to Host Conference Call to Discuss Second Quarter 2017 Financial Results on August 8, 2017 Gaithersburg, MD, August 1, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its second quarter financial and operating results following the close of U.S....More>>

Phase 2 data in older adults (E205) demonstrate adjuvants and 2-dose regimens significantly increase the magnitude, duration and quality of the RSV F Vaccine immune response   New data demonstrate that Novavax’ construct is a stable prefusogenic RSV F antigen, distinctive from other candidates,...More>>

-- Announce topline data from the Phase 2 Safety and Immunogenicity trial of the RSV F Vaccine in older adults -- Provide an Update on the RSV F Vaccine Development Program GAITHERSBURG, Md. , July 21, 2017 /PRNewswire/ --  Novavax, Inc. (Nasdaq: NVAX) today announced it will host a conference call...More>>

- Announce topline data from the Phase 2 Safety and Immunogenicity trial of the RSV F Vaccine in older adults - Provide an Update on the RSV F Vaccine Development Program GAITHERSBURG, Md. , July 17, 2017 /PRNewswire/ --  Novavax, Inc. (Nasdaq:NVAX) today announced it will host a conference call...More>>

Trial demonstrated a reduction of RSV infection in vaccinated women of greater than 50%, suggesting potential benefits to the mother, pregnancy outcomes and her infant GAITHERSBURG, Md. , June 7, 2017 /PRNewswire/ --  Novavax, Inc., (Nasdaq:NVAX) today announced that data from the second of two...More>>

GAITHERSBURG, Md. , May 11, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), today announced that Dr. James F. Cummings has been promoted to Vice President, Clinical Development and Translational Medicine. Dr. Cummings joined Novavax as Senior Director of Clinical Development in September 2015...More>>

GAITHERSBURG, Md. , May 08, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced its financial results for the first quarter ended March 31, 2017 . First Quarter Achievements: Enrollment continued during the second global season in the RSV Phase 3 Prepare™ clinical trial for...More>>

GAITHERSBURG, Md. , May 01, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2017 financial and operating results following the close of U.S. financial markets on Monday, May 8, 2017 . Conference call details are as follows: Date:      Monday,...More>>

GAITHERSBURG, Md. , Feb. 27, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced its financial results for the fourth quarter and twelve months ended December 31, 2016 . Recent and Fourth Quarter Achievements: Continued execution of the global Phase 3 Prepare™ clinical trial to...More>>

GAITHERSBURG, Md. , Feb. 20, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its fourth quarter and full year 2016 financial and operating results following the close of U.S. financial markets on Monday, February 27, 2017 ....More>>

GAITHERSBURG, Md. , Jan. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older)....More>>

GAITHERSBURG, Md. , Jan. 05, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that management will present at the 35 th Annual J.P. Morgan Healthcare Conference . Presentation details are as follows: Date: Thursday, January 12, 2017 Time: 9:30 am U.S....More>>

GAITHERSBURG, Md. , Dec. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced the Company will participate in the 4 th Annual Guggenheim Boston Healthcare Conference ....More>>

GAITHERSBURG, Md. , Nov. 30, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced the Company will participate in the Citi 2016 Global Healthcare Conference....More>>

GAITHERSBURG, Md. , Nov. 22, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced Stanley C Erck, President and Chief Executive Officer, will present at the 28 th Annual Piper Jaffray Healthcare Conference ....More>>

Announces Corporate Restructuring and Cost Savings Highlights Strategic Focus and Development Activities for 2017 GAITHERSBURG, Md. , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Financial results conference call will include Investor and Analyst webcast presentation GAITHERSBURG, Md. , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Financial results conference call will include Investor and Analyst webcast presentation GAITHERSBURG, Md. , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Oct. 07, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced it has rescheduled its 4th annual Investor and Analyst Meeting....More>>

GAITHERSBURG, Md. , Oct. 04, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced it will host its 4th annual Investor and Analyst Meeting, Tuesday, October 11, 2016 from 9:00 a.m. – 11:00 a.m. ET in New York, NY ....More>>

Topline data from the Resolve™ Phase 3 trial did not meet pre-specified efficacy objectives The attack rate for the Phase 3 primary objective was approximately 25% of that observed in Phase 2 trial   Topline data from our Phase 2 rollover trial suggest improved vaccine efficacy from a second year of...More>>

GAITHERSBURG, Md. , Sept. 07, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced it will host its 4th annual Investor and Analyst Meeting, Tuesday, October 11, 2016 from 9:00 a.m. – 11:00 a.m. ET in New York, NY ....More>>

GAITHERSBURG, Md. , Aug. 09, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced its financial results for the second quarter and six months ended June 30, 2016 . Novavax Second Quarter Achievements: Announced a new seasonal combination respiratory vaccine program....More>>

GAITHERSBURG, Md. , Aug. 02, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

(GLOBE NEWSWIRE via COMTEX) --GAITHERSBURG, Md., June 17, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), today announced that, for the third consecutive year, it has been recognized as a Top Workplace for 2016....More>>

Seasonal influenza nanoparticle approach replaces VLP program HHS BARDA contract will complete its term as scheduled in September 2016 Nanoparticle design builds on advances achieved with RSV F Vaccine Animal immunogenicity and efficacy data demonstrate broadly neutralizing antibodies Data presented...More>>

GAITHERSBURG, Md. , May 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S....More>>

GAITHERSBURG, Md. , May 12, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , May 11, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , May 04, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , April 27, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , April 13, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C....More>>

GAITHERSBURG, Md. , April 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C....More>>

GAITHERSBURG, Md. , April 04, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , March 17, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Feb. 29, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Feb. 22, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Feb. 05, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Jan. 29, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Jan. 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Jan. 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Jan. 08, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Jan. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will present at the 34 th Annual J.P....More>>

GAITHERSBURG, Md. , Dec. 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Dec. 14, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Dec. 08, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Dec. 03, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Nov. 24, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C....More>>

Conference Will Take Place November 18-20, 2015 in La Jolla, California GAITHERSBURG, Md. , Nov. 16, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Nov. 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Nov. 09, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Nov. 09, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Nov. 02, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Oct. 22, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Oct. 01, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Novavax’ Fifth Positive Top-Line Clinical Trial Announcement of the 3rd Quarter GAITHERSBURG, Md. , Sept. 29, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md., Sept....More>>

-RSV F Vaccine was safe and well-tolerated -Significant anti-F, PCA and microneutralizing antibody responses elicited in mothers -Efficient antibody transfer from mothers to infants observed -Results suggest potential to protect infants when they are most at risk GAITHERSBURG, Md. , Sept....More>>

Bill & Melinda Gates Foundation to Support Development of the RSV F Vaccine Program GAITHERSBURG, Md. , Sept. 29, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Sept. 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C....More>>

GAITHERSBURG, Md. , Sept. 15, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Sept. 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Sept. 02, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Aug. 26, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

- First respiratory syncytial virus (RSV) vaccine to demonstrate efficacy in any population - Statistically significant vaccine efficacy in prevention of symptomatic RSV disease in older adults - Large prospective epidemiological study of RSV; detected a seasonal attack rate of 4.9% for symptomatic...More>>

GAITHERSBURG, Md. , Aug. 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Aug. 05, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C....More>>

GAITHERSBURG, Md. , Aug. 03, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , July 30, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , July 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , June 19, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , June 18, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Gail K....More>>

GAITHERSBURG, Md. , June 15, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , May 7, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the first quarter 2015....More>>

GAITHERSBURG, Md. , April 30, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , April 8, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C....More>>

GAITHERSBURG, Md. , March 31, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , March 28, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , March 26, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , March 24, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , March 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Feb. 26, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Feb. 19, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Initiation of Enrollment of Phase 1 Clinical Trial of Ebola GP Vaccine   Non-Human Primate Challenge Data Signal Breakthrough in Ebola Vaccine Development   Rapid Manufacturing Process of Ebola GP Vaccine Published in BioProcessing Journal GAITHERSBURG, Md. , Feb....More>>

GAITHERSBURG, Md. , Jan. 8, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that Jill Hoyt has been named Vice President, Human Resources & Administration. Ms....More>>

GAITHERSBURG, Md. , Jan. 7, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C....More>>

GAITHERSBURG, Md. , Nov. 26, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants , today announced that Stanley C....More>>

GAITHERSBURG, Md. , Nov. 20, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S....More>>

GAITHERSBURG, Md. , Nov. 17, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Nov. 13, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today that Stanley C....More>>

GAITHERSBURG, Md. , Nov. 10, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Nov. 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Nov. 5, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Oct. 30, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Oct. 29, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S....More>>

First Ebola Vaccine Candidate based on the 2014 Guinea Ebola Strain Genetic Sequence Robust immune responses demonstrated in preclinical studies; exceptional responses when used with Novavax ' Matrix-M™ adjuvant Non-human primate study initiated GMP manufacture initiated; Scaled-up manufacturing to...More>>

GAITHERSBURG, Md. , Oct. 26, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Oct. 23, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Vaccinated Animals Generated a Broad Spectrum of Protective Antibodies Vaccine Induces Antibodies that are at Least as Protective as Palivizumab Palivizumab Competing Antibody Response from Vaccine Protects Against Both Homologous and Heterologous Disease Strains GAITHERSBURG, Md. , Oct....More>>

GAITHERSBURG, Md. , Oct. 14, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Award of Option Period for 24 months Additional Option Period Funding Commitment of $70 million Clinical, Manufacturing and Product Development Activities Funded Up to Phase 3 GAITHERSBURG, Md. , Sept. 23, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Vaccine and adjuvant were well-tolerated, consistent with the company's prior studies with saponin-based adjuvants Hemagglutination-inhibiting antibody responses similar to prior Novavax studies of A(H7N9) with another saponin adjuvant Strong neuraminidase inhibiting antibody responses in adjuvanted...More>>

GAITHERSBURG, Md. , Sept. 16, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Sept. 11, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Immunization of pregnant baboons generates anti-F IgG antibodies that are transferred from mothers to their infants When challenged with RSV, infant baboons born to immunized mothers show equivalent protection to infant baboons receiving palivizumab (Synagis ®) therapy GAITHERSBURG, Md. , Sept....More>>

GAITHERSBURG, Md. , Sept. 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Sept. 3, 2014 (GLOBE NEWSWIRE) -- In a release issued earlier today by Novavax, Inc. (Nasdaq:NVAX), the headline read " Novavax to Present RSV Vaccine Clinical and Preclinical Results at ICAAC"....More>>

GAITHERSBURG, Md. , Sept. 3, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Aug. 7, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , Aug. 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , July 30, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , June 23, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , June 19, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , June 18, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that on June 12, 2014 , the Honorable John O....More>>

GAITHERSBURG, Md. , June 11, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , June 5, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , June 4, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , June 2, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Stanley C....More>>

Sustained levels of RSV F antibody and palivizumab-competing antibody responses demonstrated over a 4 to 6 month period Results support accelerating development plans for "seasonal" elderly RSV vaccine Phase 2 clinical trial in elderly anticipated to start in late-2014/early-2015 GAITHERSBURG, Md....More>>

GAITHERSBURG, Md. , May 7, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , May 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , May 1, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will report its first quarter 2014 financial results on Wednesday, May 7, 2014 after the close of the U.S. financial markets....More>>

University of Maryland School of Medicine Study Published in Vaccine Highlights First Potential Effective Means for Preventing MERS Coronavirus Outbreak BALTIMORE and GAITHERSBURG, Md. , April 30, 2014 (GLOBE NEWSWIRE) -- The University of Maryland School of Medicine ( UM SOM ) and Novavax, Inc....More>>

Vaccine candidate was well-tolerated with no vaccine-related serious adverse events Highest immune responses observed with a single dose of vaccine combined with aluminum phosphate adjuvant Women with the lowest baseline levels of RSV neutralizing antibodies had the largest increases following immun...More>>

GAITHERSBURG, Md. , April 7, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Cynthia N. Oliver , Ph.D....More>>

GAITHERSBURG, Md. , April 2, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Stanley C....More>>

GAITHERSBURG, Md. , March 10, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

GAITHERSBURG, Md. , March 10, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of John J....More>>

GAITHERSBURG, Md. , Feb. 27, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today the execution of a contract modification to extend the base period of performance of its current contract with the U.S....More>>

ROCKVILLE, Md. , Feb. 19, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will host a conference call and webcast to report its fourth quarter and year-end 2013 financial results on Monday, March 10, 2014 , at 4:30 p.m. ET ....More>>

ROCKVILLE, Md. , Jan. 13, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced the continuation of their partnership with PATH to develop Novavax ' RSV (respiratory syncytial virus) vaccine for maternal immunization....More>>

ROCKVILLE, Md. , Jan. 13, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced a number of promotions within its clinical operations group in preparation for expanded clinical trial activities in 2014 and 2015. Gregory M. Glenn , M.D....More>>

ROCKVILLE, Md. , Nov. 26, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C....More>>

ROCKVILLE, Md., Nov 13, 2013 (GLOBE NEWSWIRE via COMTEX) -- Data are industry's first from clinical trial of vaccine against A(H7N9) strain of influenza 81% of 5ug adjuvanted vaccine recipients had protective HAI levels 97% of 5ug adjuvanted vaccine recipients had anti-neuraminidase antibody respons...More>>

ROCKVILLE, Md. , Nov. 7, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , Oct. 30, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will host a conference call and live webcast to report its third quarter 2013 financial results on Thursday, November 7, 2013 , at 4:30 p.m. ET ....More>>

ROCKVILLE, Md. , Oct. 7, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 2 dose-confirmatory clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age....More>>

ROCKVILLE, Md. , Sept. 27, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , Sept. 24, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Quadrivalent Seasonal Influenza Clinical Trial to start in 1Q2014 Pandemic Influenza Clinical Trial to start in the U.S. in 1H2014 Proprietary Adjuvant Matrix-M to be used in the Pandemic Clinical Trial ROCKVILLE, Md. , Sept. 24, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , Sept. 17, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Genocea Biosciences' Herpes Simplex Therapeutic Vaccine uses Matrix-M adjuvant Phase 1/2A U.S.-based clinical trial enrolled 143 volunteers with moderate-to-severe HSV-2 Two highest dose Matrix-M adjuvanted cohorts demonstrated statistically significant reductions in viral shedding Genocea's Phase 2...More>>

ROCKVILLE, Md. , Sept. 11, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , Sept. 5, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc . (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck , President and Chief Executive Officer, will present at the 2013 Stifel Nicolaus Healthcare Conference on Thursday, September 12, 2013 at 9:45 a.m....More>>

ROCKVILLE, Md. , Sept. 3, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , Aug. 8, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , Aug. 6, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C....More>>

ROCKVILLE, Md. , Aug. 1, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will host a conference call and live webcast to report its second quarter 2013 financial results on Thursdsay, August 8, 2013 , at 8:30 a.m. ET ....More>>

Positive efficacy data from its A(H7N9) vaccine published in the peer-reviewed scientific journal Vaccine Novavax vaccine-induced immunity provided 100% protection against lethal wild-type A(H7N9) influenza challenge versus 0% survival in control (H5N1) vaccine and placebo groups Achieved complete c...More>>

ROCKVILLE, Md. , July 8, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Well-tolerated without any vaccine-related serious adverse events Adjuvant enhanced response seen in all dose levels Anti-F IgG antibodies to the F protein in serum rose 3.0-5.7 fold across all dose levels Palivizumab-like antibodies rose from undetectable levels to those previously associated with...More>>

ROCKVILLE, Md. , June 24, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the appointment of Barclay A. "Buck" Phillips to the position of Senior Vice President and Chief Financial Officer, effective June 24, 2013 ....More>>

ROCKVILLE, Md. , June 6, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it had successfully produced a vaccine candidate designed to provide protection against the recently emerging Middle East Respiratory Syndrome Coronavirus (MERS-CoV)....More>>

Adds proprietary nanoparticle matrix immune-modulating adjuvant technology to Novavax's recombinant vaccine development platform Total transaction valued at approximately $29.6 million USD Conference call with management to discuss acquisition at 10:00 a.m. EDT today ROCKVILLE, Md....More>>

Novavax H7N9 VLP vaccine produced, purified and entered into preclinical immunogenicity and efficacy studies in less than a month Production of GMP H7N9 clinical trial materials underway ROCKVILLE, Md. , May 10, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Key Highlights Phase II RSV clinical trial data achieve protocol specified-objectives of safety and immunogenicity....More>>

ROCKVILLE, Md. , April 26, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will report its 2013 first-quarter financial results on Tuesday, May 7, 2013 , before the U.S. financial markets open....More>>

ROCKVILLE, Md. , April 25, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that Stanley C....More>>

ROCKVILLE, Md. , April 15, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will review recent clinical results from the company's vaccine development programs at the World Vaccine Congress and Expo this week in Washington, DC ....More>>

ROCKVILLE, Md. , April 10, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the appointment of Amy B. Fix to the position of Vice President of Regulatory Affairs....More>>

Well-tolerated and without any vaccine related serious adverse events (SAEs) Anti-F IgG antibodies to the F protein in serum rose 6 to 16-fold across all doses (60 and 90 µg)....More>>

ROCKVILLE, Md. , March 18, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) reported that David C....More>>

ROCKVILLE, Md. , March 13, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C....More>>

ROCKVILLE, Md. , March 8, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , March 1, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced financial results for the fourth quarter and year-ended December 31, 2012 ....More>>

ROCKVILLE, Md. , Feb. 22, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will report its 2012 fourth-quarter and year-end financial results on Friday, March 1, 2013 , before the U.S. financial markets open....More>>

ROCKVILLE, Md. , Feb. 7, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Frederick W....More>>

ROCKVILLE, Md. , Jan. 24, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that the U.S....More>>

Vaccine was well-tolerated with no evident dose-related toxicity or attributable SAEs Immunization induced significant increases in neutralizing antibody responses ROCKVILLE, Md. , Dec. 6, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , Dec. 3, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , Nov. 20, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C....More>>

ROCKVILLE, Md. , Nov. 12, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C....More>>

ROCKVILLE, Md. , Nov. 2, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced financial results for the third quarter and nine months ended September 30, 2012 ....More>>

ROCKVILLE, Md. , Oct. 26, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will report its 2012 third-quarter financial results on Friday, November 2, 2012 , before the U.S. financial markets open....More>>

ROCKVILLE, Md. , Oct. 23, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Vaccine candidates met safety and immunogenicity endpoints in both trials Trials' results support further development of vaccine in larger trials -- Adjuvanted candidates, at all doses of antigen tested including 3.75 µg dose, achieved dose-sparing goals with seroconversion and seroprotection rates...More>>

ROCKVILLE, Md. , Oct. 15, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 1 dose-ranging clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adults 60 years of age and older....More>>

ROCKVILLE, Md. , Oct. 8, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 2 dose-ranging clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age....More>>

Data Reinforce Previous Clinical and Preclinical Studies Successfully Induced F-Protein Specific Neutralizing Antibody Response Phase 2 Studies to Begin in the Fourth Quarter of 2012 ROCKVILLE, Md. , Sept. 27, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , Sept. 6, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C....More>>

ROCKVILLE, Md. , Sept. 4, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C....More>>

ROCKVILLE, Md. , Aug. 13, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Stanley C....More>>

ROCKVILLE, Md. , Aug. 3, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced its financial results for the second quarter and six months ended June 30, 2012 ....More>>

ROCKVILLE, Md. , July 27, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will report its 2012 second-quarter financial results on Friday, August 3, 2012 , before the U.S. financial markets open....More>>

Primary Endpoints Achieved in Phase II Seasonal Influenza Trial Two H5N1 Pandemic Influenza Trials Fully Enrolled ROCKVILLE, Md. , July 24, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

Novavax initially awarded approximately $2 million by PATH Potential for future PATH funding of 50% of external costs to develop maternal RSV vaccine available for low-resource countries Novavax retains global rights to commercialize RSV vaccine ROCKVILLE, Md....More>>

ROCKVILLE, Md. , July 16, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), CPL Biologicals (CPLB) and the International Centre for Genetic Engineering and Biotechnology (ICGEB), today announced that they have formed a new collaboration to develop a novel malaria vaccine in India ....More>>

ROCKVILLE, Md. , July 5, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , June 27, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , June 4, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Stanley C....More>>

ROCKVILLE, Md. , May 21, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that on Friday, May 18, 2012 , it sold 10,000,000 shares of its common stock to RA Capital Healthcare Fund, LP at a price of $1.22 per share....More>>

ROCKVILLE, Md. , May 9, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , May 4, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced its financial results for the first quarter ended March 31, 2012 ....More>>

ROCKVILLE, Md. , May 2, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md. , April 26, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will report its 2012 first-quarter financial results on Friday, May 4, 2012 , before the U.S. financial markets open....More>>

ROCKVILLE, Md. , April 3, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Frederick W....More>>

ROCKVILLE, Md. , March 22, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that Louis F....More>>

ROCKVILLE, Md. , March 12, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Stanley C....More>>

ROCKVILLE, Md. , March 9, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced financial results for the fourth quarter and year ended December 31, 2011 ....More>>

ROCKVILLE, Md. , March 8, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today the appointment of Mr. John A. Herrmann III to the position of Vice President and General Counsel. Mr....More>>

ROCKVILLE, Md. , March 1, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it has begun enrollment in a Phase II clinical trial of its quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate....More>>

ROCKVILLE, Md. , Feb. 24, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will report its 2011 fourth-quarter and year-end financial results on Friday, March 9, 2012 , before the U.S. financial markets open....More>>

ROCKVILLE, Md. , Feb. 10, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Frederick W....More>>

ROCKVILLE, Md. , Feb. 1, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today the appointment of Mr. Mervyn L. Hamer to the position of Vice President of Manufacturing. In this role, Mr....More>>

Regulatory approval received for rabies vaccine toxicology studies in India Clinical study of influenza vaccine candidate planned for 2012 Validated manufacturing facility ready for clinical production Additional new vaccines in development for undisclosed targets ROCKVILLE, Md. , Jan....More>>

ROCKVILLE, Md., Nov 28, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C....More>>

ROCKVILLE, Md. , Nov. 21, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it has entered a long-term lease arrangement for 74,000-square-feet of manufacturing, lab and office space in two facilities in Gaithersburg, MD ....More>>

ROCKVILLE, Md., Nov 10, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Frederick W....More>>

ROCKVILLE, Md., Nov 7, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc. (Nasdaq:NVAX) announced today the appointment of Russell P. "Rip" Wilson as Senior Vice President of Business Development. Mr....More>>

ROCKVILLE, Md., Nov 4, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc. (Nasdaq:NVAX) today announced financial results for the third quarter ended September 30, 2011....More>>

ROCKVILLE, Md., Nov 3, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc. (Nasdaq:NVAX) announced today the appointment of Erica Shane, Ph.D., to the position of Vice President, Process Development. In this role, Dr. Shane will have responsibility for all process development activities for Novavax....More>>

ROCKVILLE, Md., Oct 28, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc. (Nasdaq:NVAX) will report financial results for the third fiscal quarter of 2011 on Friday, November 4, 2011, before the U.S. financial markets open....More>>

ROCKVILLE, Md., Oct 27, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc. (Nasdaq:NVAX) today announced that Stanley C....More>>

ROCKVILLE, Md., Oct 10, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc....More>>

ROCKVILLE, Md., Oct 5, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it has been awarded a $1.3 million contract from the U.S....More>>

Oct 3, 2011 (GlobeNewswire via COMTEX) -- - Well-tolerated with no systemic side-effect trends - Highly immunogenic with an increase in anti-RSV antibodies in 100% of subjects in the highest-dose group - Oral and poster presentations to be made at 5th Vaccine and ISV Annual Global Conference in Seat...More>>

ROCKVILLE, Md., Sep 26, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc....More>>

Sep 8, 2011 (GlobeNewswire via COMTEX) -- VLP vaccine candidate was well-tolerated, immunogenic and generated cross-reactive neutralizing antibodies ROCKVILLE, Md., Sept. 8, 2011 (GLOBE NEWSWIRE) -- Novavax, Inc....More>>

ROCKVILLE, Md., Sep 6, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Stanley C....More>>

ROCKVILLE, Md., Aug 16, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C....More>>

ROCKVILLE, Md., Aug 5, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc. (Nasdaq:NVAX) today announced financial results for the second quarter ended June 30, 2011....More>>

ROCKVILLE, Md., Aug 4, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc....More>>

ROCKVILLE, Md., Jul 29, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc. (Nasdaq:NVAX) will report financial results for the second quarter of 2011 on Friday, August 5, 2011, before the U.S. financial markets open....More>>

ROCKVILLE, Md., Jun 28, 2011 (GlobeNewswire via COMTEX) -- Novavax, Inc. (Nasdaq:NVAX) announced today the appointment of Timothy J. Hahn, Ph.D., as Senior Vice President of Manufacturing. Dr....More>>

ROCKVILLE, Md., May 13, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc....More>>

ROCKVILLE, Md., May 11, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) has been named Biotechnology Firm of the Year by the Tech Council of Maryland (TCM), the largest technology trade group serving the advanced technology and biotechnology communities of Maryland ....More>>

ROCKVILLE, Md., May 9, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results for the first quarter ended March 31, 2011 ....More>>

ROCKVILLE, Md., May 3, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) will report financial results for the first quarter of 2011 on Monday, May 9, 2011 , before the U.S. financial markets open. The announcement will be followed by a webcast and conference call hosted by Stanley C....More>>

ROCKVILLE, Md., April 26, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointments of Louis Fries III , M.D., as Vice President, Clinical and Medical Affairs, and Jane Halpern , Ph.D., as Vice President of Regulatory Affairs. Before joining Novavax, Dr....More>>

- Stanley Erck appointed President & CEO - James Young, Ph.D. becomes Chairman of the Board ROCKVILLE, Md., April 19, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Stanley C....More>>

ROCKVILLE, Md., April 5, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc. (NASDAQ: NVAX) announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine as one of the top "100 great investigational drugs in development" today....More>>

ROCKVILLE, Md., March 28, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the fourth quarter and year ended December 31, 2010 ....More>>

ROCKVILLE, Md., March 23, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2010 year-end financial results in a press release to be issued after 8:00 a.m....More>>

ROCKVILLE, Md., March 22, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr....More>>

ROCKVILLE, Md., March 11, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc....More>>

-- BARDA contract valued at up to $179 Million to Develop Pandemic and Seasonal Influenza Vaccines for U.S. Government Using Recombinant VLP Technology -- Includes $97 Million 3-year Base Period and $82 Million 2-year Option Period Press Conference at 9:15 a.m....More>>

-- Contract Includes $97 Million 3-year Base Period and $82 Million 2-year Option Period -- Base Period Will Fund Seasonal Influenza Vaccine through Phase 3 and Potential FDA Licensure; Pandemic Influenza Vaccine Candidates through Phase 1/2 Clinical Trials -- Includes Development of Manufacturing P...More>>

- 15 million dose South Korean market - LG to build manufacturing facility with 30 million dose influenza vaccine capacity ROCKVILLE, Md., March 1, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc....More>>

ROCKVILLE, Md., Feb. 24, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr....More>>

ROCKVILLE, Md., Feb. 18, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc....More>>

ROCKVILLE, Md., Feb. 10, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr....More>>

ROCKVILLE, Md., Feb. 9, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr....More>>

Vaccine candidate targets world's leading cause of infant death and childhood respiratory disease ROCKVILLE, Md., Jan. 4, 2011 /PRNewswire via COMTEX/ -- Novavax, Inc....More>>

Vaccine candidate completely protects mice from RSV replication in the lungs ROCKVILLE, Md., Dec. 22, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) and scientists at the University of Massachusetts Medical School , led by Dr....More>>

ROCKVILLE, Md., Dec. 16, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S....More>>

ROCKVILLE, Md., Nov. 29, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax, will be presenting at the Piper Jaffray 22nd Annual Healthcare Conference....More>>

ROCKVILLE, Md., Nov. 11, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the Lazard 7th Annual Healthcare Conference....More>>

ROCKVILLE, Md., Nov. 5, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the third quarter ended September 30, 2010....More>>

ROCKVILLE, Md., Nov. 4, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has been awarded approximately $978,000 in grants under the Internal Revenue Service's Qualifying Therapeutic Discovery Project ("QTDP")....More>>

ROCKVILLE, Md., Oct 15, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Dr....More>>

ROCKVILLE, Md., Sept 29, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, announced today that Mr. Frederick Driscoll, Chief Financial Officer of Novavax, will be presenting at the BIO Investor Forum....More>>

ROCKVILLE, Md., Sept 08, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Mr. Frederick Driscoll, Chief Financial Officer of Novavax will be presenting at the Stifel Nicolaus Conference....More>>

ROCKVILLE, Md., Sept 08, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the company will be presenting at the American Society for Microbiology (ASM) sponsored, ICAAC....More>>

ROCKVILLE, Md., Aug 19, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) President and CEO Dr. Rahul Singhvi today attended the press briefing by U.S....More>>

ROCKVILLE, Md., Aug 17, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the company will be presenting at the IMVAC Summit. The Conference will take place August 17-19, 2010 at the Royal Sonesta Hotel, Cambridge, MA. Dr....More>>

ROCKVILLE, Md., Aug 12, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) reported today that results from a pre-clinical toxicology study of its vaccine candidate to prevent respiratory syncytial virus (RSV), showed the vaccine to be safe and well-tolerated at all doses tested....More>>

ROCKVILLE, Md., Aug 06, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the second quarter ended June 30, 2010....More>>

ROCKVILLE, Md., Aug 06, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointment of Richard Douglas, Ph.D. to its board of directors. Dr. Douglas is currently Senior Vice President, Corporate Development at Genzyme Corp....More>>

ROCKVILLE, Md., July 30, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Dr....More>>

Patent claims cover technology for rapid, efficient, and uniform production of VLP vaccines from strains of seasonal and pandemic influenza. ROCKVILLE, Md., July 27, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the issuance of U.S. Patent No....More>>

ROCKVILLE, Md., July 6, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointment of Gregory Glenn, M.D., as the company's Chief Scientific Officer who will report to Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax. Previously, Dr....More>>

ROCKVILLE, Md., June 18, 2010 /PRNewswire via COMTEX/ --Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr....More>>

Promotions reflect substantial progress in improving manufacturing process ROCKVILLE, Md., June 14, 2010 /PRNewswire via COMTEX/ --Novavax, Inc. (Nasdaq: NVAX) announced today the appointments of John W....More>>

- CPL Biologicals state-of-the-art vaccine facility operational in Dholka, India - Validation testing to begin this month - Annual bulk production capacity projected at 60 million doses of VLP influenza vaccine - Sterile filling capacity available ROCKVILLE, Md., June 10, 2010 /PRNewswire via COMTEX...More>>

ROCKVILLE, Md., May 24, 2010 /PRNewswire via COMTEX/ --Novavax, Inc. (Nasdaq: NVAX) announced today the appointment of Mark O. Thornton, M.D., M.P.H., Ph.D., as the company's Senior Vice President, Development and Chief Medical Officer. Before joining Novavax, Dr....More>>

First report of a vaccine protecting ferrets against the 2009 pandemic H1N1 virus is published in the journal Vaccine ROCKVILLE, Md., May 13, 2010 /PRNewswire via COMTEX/ --Novavax, Inc....More>>

ROCKVILLE, Md., May 10, 2010 /PRNewswire via COMTEX/ --Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the first quarter ended March 31, 2010....More>>

ROCKVILLE, Md., May 4, 2010 /PRNewswire via COMTEX/ --Novavax, Inc. (Nasdaq: NVAX) announced today that Dr....More>>

-- Both 15 and 60 mcg doses well-tolerated and immunogenic in older adults 60 years or higher in age -- Preliminary evidence shows improved immunogenicity at higher VLP dose ROCKVILLE, Md., April 29, 2010 /PRNewswire via COMTEX/ --Novavax, Inc....More>>

ROCKVILLE, Md., April 22, 2010 /PRNewswire via COMTEX/ --Novavax, Inc....More>>

ROCKVILLE, Md., April 7, 2010 /PRNewswire via COMTEX/ --Novavax, Inc. (Nasdaq: NVAX) announced today that it has appointed James F. Young, Ph.D., to its Board of Directors. Dr. Young will be an independent Board Member effective immediately. Dr....More>>

ROCKVILLE, Md., March 29, 2010 /PRNewswire via COMTEX/ --Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, released the final results from a Phase II clinical trial evaluating Novavax's trivalent seasonal influenza Virus-like particle (VLP) vaccine candidate in healthy adults....More>>

-- Independent Data Safety Monitoring Board (DSMB) concludes that Novavax's 2009 H1N1 VLP pandemic influenza vaccine is well-tolerated and induces robust immune responses with a single injection at all dose levels tested -- Stage B enrollment completed with over 3,500 volunteers in the trial ROCKVIL...More>>

ROCKVILLE, Md., March 12, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq:NVAX)today announced financial results for the fourth quarter and year ended December 31, 2009....More>>

ROCKVILLE, Md., March 11, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the 22nd Annual ROTH OC Growth Stock Conference....More>>

Enrollment in largest clinical study in Novavax's history of over 4,500 subjects completed in less than 5 months ROCKVILLE, Md., March 8, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc....More>>

ROCKVILLE, Md., March 5, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at Cowen and Company's 30th Annual Health Care Conference....More>>

ROCKVILLE, Md., March 4, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2009 year-end financial results in a press release to be issued after 8:00 a.m. local time on Friday, March 12, 2010....More>>

- Positive Clinical Results from Pivotal Study of H1N1 Virus-Like Particle (VLP) Pandemic Influenza Vaccine in Mexico - Immunogenicity responses at all dose levels meet U.S....More>>

ROCKVILLE, Md., Feb 18, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it received a notice of deficiency, as expected, from the NASDAQ Stock Market (NASDAQ) listing qualifications department. As a result of the election of Stanley C....More>>

ROCKVILLE, Md., Feb 18, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that Fast Company has placed Novavax as one of the Top Ten Most Innovative Companies in the Biotech industry....More>>

ROCKVILLE, Md., Feb 16, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) The Board of Directors of Novavax, Inc., announced today the election of Stanley Erck as Executive Chairman. The effective date of this leadership change is immediately. Previously, Mr....More>>

Data show significant Neuraminidase Inhibition Antibody Titers in VLP vaccine recipients ROCKVILLE, Md., Feb 08, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc....More>>

ROCKVILLE, Md., Feb 08, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc....More>>

ROCKVILLE, Md., Feb 08, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr....More>>

ROCKVILLE, Md., Jan 25, 2010 /PRNewswire via COMTEX/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the company will be presenting at the upcoming Phacilitate Vaccine Forum Washington 2010....More>>

- Recombinant F protein particle vaccine candidate protects cotton rats against live RSV - No evidence of enhanced disease in lungs of vaccinated animals challenged with RSV - Manufacturing process successfully scaled to produce cGMP material for toxicology study ROCKVILLE, Md., Jan 12, 2010 /PRNews...More>>

ROCKVILLE, Md., July 9 /PRNewswire-FirstCall/ -- Novavax, Inc....More>>

ROCKVILLE, Md., July 5 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) said today that Len Stigliano has been appointed Vice President, Chief Financial Officer and Treasurer, effective July 2, 2007. Mr....More>>

ROCKVILLE, Md., June 21 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Rick A. Bright, Ph.D., vice president of global influenza programs, and co-authors received the Centers for Disease Control's Charles C....More>>

ROCKVILLE, Md., June 18 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has reached agreement with 100% of the noteholders of its outstanding convertible notes to revise the conversion price and eliminate the redemption right(s) of the noteholders....More>>

ROCKVILLE, Md., June 14 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) Chief Executive Officer Dr. Rahul Singhvi will present at the 2nd Annual Piper Jaffray London Health Care Conference at 4:40 p.m. local time at the Great Eastern Hotel in London on June 21, the company announced today....More>>

ROCKVILLE, Md., June 8 /PRNewswire-FirstCall/ -- Novavax Inc. Chief Executive Officer Dr. Rahul Singhvi will present at the 6th Annual Needham & Co. Biotechnology and Medical Technology Conference at 8 a.m. on Thursday, June 14 at the New York Palace Hotel in New York, the company announced today....More>>

Study Presented at Second International Conference on Avian Influenza at France's Pasteur Institute PARIS, June 1 /PRNewswire-FirstCall/ -- Very low doses of Novavax Inc.'s pandemic influenza vaccine provided protection against a lethal challenge of live H5N1 viruses, according to pre-clinical data...More>>

ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ -- Novavax Inc. Chief Executive Officer Dr. Rahul Singhvi will present at Friedman, Billings, Ramsey & Co.'s 2007 Growth Conference at 3:50 p.m. Eastern Time on Wednesday, May 30 at the Grand Hyatt Hotel, New York, the company announced today. Dr....More>>

ROCKVILLE, Md., May 11 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) today reported financial results for the first quarter ended March 31, 2007....More>>

ROCKVILLE, Md., May 4 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) Chief Executive Officer Dr....More>>

Ferret Study to be Part of Data Package Required to Begin Clinical Trials ROCKVILLE, Md., May 3 /PRNewswire-FirstCall/ -- Novavax Inc....More>>

ROCKVILLE, Md., May 1 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2007 first quarter financial results in a press release to be issued after 7:00 a.m. Eastern Time on May 11, 2007....More>>

Jeffrey W. Church Resigns as Chief Financial Officer ROCKVILLE, Md., April 5 /PRNewswire-FirstCall/ -- Novavax Inc. today appointed Len Stigliano as interim Chief Financial Officer to replace Jeffrey W. Church, who is leaving later this month to accept a position with another company....More>>

Study Published in Vaccine Shows Strong Immune Response, Protection Against H9N2 Influenza Strain ROCKVILLE, Md., April 2 /PRNewswire-FirstCall/ -- Novavax Inc.'s virus- like particle (VLP) vaccine triggered a robust immune response and provided protection against the H9N2 strain of avian influenza,...More>>

ROCKVILLE, Md., March 14 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) has appointed James M. Robinson Vice President of Technical and Quality Operations, the company said today....More>>

ROCKVILLE, Md., March 14 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) today announced financial results for the fourth quarter and year ended Dec. 31, 2006....More>>

Gary C. Evans to Serve as Lead Director ROCKVILLE, Md., March 8 /PRNewswire-FirstCall/ -- (Nasdaq: NVAX) Novavax Inc.'s Board of Directors has elected vaccine expert John Lambert as Executive Chairman of the Board....More>>

ROCKVILLE, Md., March 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2006 fourth quarter and full-year financial results in a press release to be issued after 7:00 a.m. Eastern Time on March 14, 2007....More>>

ROCKVILLE, Md., March 2 /PRNewswire-FirstCall/ - Novavax Inc. (Nasdaq: NVAX) announced today that it has entered into a worldwide exclusive agreement to license a new virus-like particle (VLP) technology from the University of Massachusetts Medical School (UMMS) in Worcester....More>>

Data Demonstrate Broad, Robust Immune Response to VLP Vaccine ROCKVILLE, Md., Feb. 21 /PRNewswire-FirstCall/ -- Novavax, Inc....More>>

ROCKVILLE, Md., Feb. 7 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) Chief Executive Officer Dr. Rahul Singhvi will present at the BIO CEO & Investor Conference at 12:45 p.m. on Feb. 13 at The Waldorf=Astoria Hotel in New York, the company announced today. Dr....More>>

ROCKVILLE, Md., Jan 23, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Novavax Inc. (Nasdaq: NVAX) said today that Dr....More>>

First Data From Live-Virus Challenge Study Show Robust Immune Response and Cross-Protection in Pre-Clinical Models BALTIMORE, Jan 22, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Novavax, Inc.'s (Nasdaq: NVAX) novel virus-like particle (VLP) vaccines have been shown to be effective in gene...More>>

ROCKVILLE, Md., Jan. 17 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) today announced the company's participation in the Phacilitate Vaccine Forum, a three-day conference that begins Monday at the Marriott Waterfront Hotel in Baltimore, MD....More>>

Plans Under Way to Advance New Vaccine Into Clinical Testing ROCKVILLE, Md., Jan. 16 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) said today that it has significantly enhanced both the quality and purity of its virus-like particle (VLP) vaccine for HIV/AIDS....More>>

Research Labs, Business Offices to be Housed Together in State-of-the-Art Facility in Rockville MALVERN, Pa., Dec. 13 /PRNewswire-FirstCall/ -- Novavax, Inc....More>>

MALVERN, Pa., Dec 05, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Novavax Inc. (Nasdaq: NVAX) Chief Executive Officer Dr. Rahul Singhvi will present at the BMO Nesbitt Burns Healthcare Conference on December 6 at the Millennium Broadway Hotel in New York, the company announced today. Dr....More>>

MALVERN, Pa., Nov. 22 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission ("SEC")....More>>

MALVERN, Pa., Nov 14, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Novavax Inc. (Nasdaq: NVAX), today announced its financial results for the third quarter ended September 30, 2006....More>>

New Data Presented at World Congress on Vaccines, Immunization and Immunotherapy MONTREAL, Nov....More>>

MALVERN, Pa., Nov. 7 /PRNewswire-FirstCall/ -- (Nasdaq: NVAX) - Novavax, Inc. today announced that it will report its third quarter financial results in a press release to be issued after 7:00 a.m. EST on Nov. 14, 2006....More>>

MALVERN, Pa., Nov. 1 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) -- Novavax, Inc. Chief Executive Officer, Dr. Rahul Singhvi, will present at Rodman & Renshaw's 8th Annual Healthcare Conference on November 7 at the New York Palace Hotel in New York, the company announced today. Dr....More>>

First Opportunity To Test Novel Vaccine Against Live Virus MALVERN, Pa., Oct. 31 /PRNewswire-FirstCall/ -- (Nasdaq: NVAX) - Novavax, Inc. said today the U.S....More>>

LYON, France, Oct. 10 /PRNewswire-FirstCall/ -- Novavax Inc.'s (Nasdaq: NVAX) unique cell culture manufacturing system has the potential to produce up to several million doses of vaccine within six months of an influenza pandemic, the Company said here today at the World Vaccine Congress....More>>

MALVERN, Pa., Oct. 2 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today named Penny Heaton, M.D., to the newly created position of Chief Medical Officer, effective Oct. 9. Dr....More>>

MALVERN, Pa., Sept. 21 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) -- Novavax, Inc. President and Chief Executive Officer, Dr. Rahul Singhvi, will present at the UBS Global Life Sciences Conference on September 26 at the Grand Hyatt Hotel in New York, the company announced today. Dr....More>>

New Delivery Route May Provide Alternative to Administration by Injection MALVERN, Penn., Sept. 19 /PRNewswire-FirstCall/ -- Novavax, Inc....More>>

MALVERN, Pa., Sept. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) said today that the company's board has unanimously elected Dr. Tom Monath to be a new director, effective immediately. Dr....More>>

MALVERN, Pa., Aug. 17 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) said today that Jeffrey Church has been appointed Vice President, Chief Financial Officer and Treasurer, effective September 5, 2006. Mr....More>>

MALVERN, Pa., Aug. 14 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the second quarter ended June 30, 2006....More>>

MALVERN, Pa., Aug. 2 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its second quarter financial results in a Press Release to be issued after 7:00 a.m. EDT on August 14, 2006....More>>

Novavax to begin pre-clinical testing immediately MALVERN, Pa., July 31 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) -- Novavax Inc. said today its scientists have succeeded in making a vaccine candidate designed to protect against the H5N1 clade 2 influenza virus....More>>

Two Key Collaborators Validate Novavax's Proprietary VLP Technology MALVERN, Pa., July 18 /PRNewswire-FirstCall/ -- Novavax Inc....More>>

Action Resolves Notice Letter from Nasdaq MALVERN, Pa., July 12 /PRNewswire-FirstCall/ -- Novavax, Inc....More>>